ClinicalTrials.gg
RecruitingNCT07940972Updated Nov 17, 2026

Evaluation of Self-Assembling Peptides (Curodont Protect) in Managing Post Bleaching Hypersensitivity

An interventional study of self assembling peptide p11-4 with fluoride and Sodium Fluoride and Potassium Nitrate in Post Bleaching Hypersensitivity and Hypersensitivity Dentin, sponsored by Nahda University. Recruiting at 1 site in Egypt. Open to participants aged 18 Weeks to 40 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Nahda University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2026, registered Nov 2026).
  • Started Jan 2026; still recruiting 9 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Weeks to 40 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Dentin Sensitivity with a site in Egypt — 8 open to participants now, 10 under way, 1 of them phase 3. Dentin Sensitivity · Egypt.

Planned enrollment
30th of 34
20 · median 47
Started
2026
with 3 others
No phase
26 of 35
7 open now
Registered
34th of 35
by date
Lead sponsor
2 of 35
Nahda University

Among the 35 studies in Dentin Sensitivity with a site in Egypt, this one is the 30th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 26 with no phase, and was the 34th registered.

Dentin Sensitivity

291 studies on the registry are indexed under Dentin Sensitivity; 49 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

8 of the 35 studies in Dentin Sensitivity with a site in Egypt are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 20 Dentin Sensitivity studies recruiting now, 6 (30%) set no upper age limit and 13 (65%) stop at 75 or younger; 2 take children under 18; 12 take healthy volunteers.

This study: 18 Weeks to 40 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Dentin Sensitivity with a site in Egypt, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if using self assembling peptides reduce post operative bleaching hypersensitivity in middle aged patients (18-40).

Research will evaluate the efficacy of self-assembling peptide in reducing hypersensitivity after bleaching compared to Potassium Nitrate and Sodium Fluoride participants will all recive the same bleaching kit and protocol following the intruction provided by bleaching kit Will then be assorted into two groups which one will recive Potassium Nitrate and Sodium Fluoride and the other with recive self assembling peptide post bleaching Hypersensitivity will be evaluated immediately after the bleaching procedure , immediately after the application of the remineralizing/desensitizing agent , after 24 hours , and after one week

03

Conditions studied

  • Post Bleaching Hypersensitivity
  • Hypersensitivity Dentin

Browse trials for

04

Who can participate

Ages eligible
18 Weeks to 40 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 40 years.
  • All teeth that need bleaching are free from caries, filings or periodontal disease. - Low caries index.
  • Patients with VITA- color teeth shade A2 or darker.
  • Patients with cooperative behavior and medically free.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe intrinsic discoloration.
  • Patient with history of teeth .
  • Taking analgesics/anti-inflammatory drugs at the time of the study, pregnancy, and smoking.
  • Any professional desensitizing therapy on the selected teeth during the last 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Power white After Whitening Mousse

    Drug: Sodium Fluoride and Potassium Nitrate

  • Active comparator
    Curodont protect

    Drug: self assembling peptide p11-4 with fluoride

Interventions

  • Drugself assembling peptide p11-4 with fluoride

    Apply the gel over the entire dentition or targeted teeth using a microbrush. Leave the gel undisturbed for 1 to 2 minutes. The patient can spit out any excess residue, but do not rinse immediately with water to allow the active ingredients to maintain contact with the enamel. For sensitive teeth or professional cleanings/bleaching, apply 2 minutes before and after the procedure

  • DrugSodium Fluoride and Potassium Nitrate

    Dispense a small amount and apply a thin layer of the After Whitening Mousse directly onto the surface of the teeth Allow the mousse to remain on the teeth for 10 to 15 minutes. The patient can often leave the dental practice with the mousse still applied

06

What researchers measure

Primary outcomes

  1. The Effect of Self Assembling Peptides on treatment of post bleaching hypersensitivity using Visual Analog scale for assessment

    Time frame: from bleaching day up to 7 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 112 non-industry interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 12. This study's planned 11 months is above that.

Counting every sponsor, half of 146 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 17, 2026
StartActual
Jan 18, 2026
Primary completionEst.
Dec 18, 2026
CompletionEst.
Jan 18, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940972
Lead sponsor
Nahda University
Responsible party
Ahmed Ezzat Mohamed Mohamed Kamel (Bachelor's degree, Nahda University) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 18, 2026
Primary completion
Dec 18, 2026 (estimated)
Completion
Jan 18, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Ahmed Ezzat Kamel, bachelor degree
Contact
Ahmed.ezzat1025@nub.edu.eg
+201091010062

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion